Research Journal of Medical Sciences
ISSN: Online 1993-6095ISSN: Print 1815-9346
Abstract
Use of surfactant have markedly improved the survival of preterm, LBW, and VLBW infants and have resulted in reduced neonatal and infant mortality. With adequate antenatal steroids, early CPAP and early surfactant therapy improves survival outcome. Present study was aimed to study use of surfactant in SNCU of a tertiary hospital. Present study was single‐center, prospective, observational study, conducted in newborns between 24‐37 weeks (GA) admitted in SNCU of our tertiary hospital, Neonates meeting inclusion criteria received bolus doses of natural (bovine or porcine) surfactant at a dose of 100 mg kgG1 of phospholipids. In present study, total neonates, in whom surfactant administered during July 2022 to July 2023) were 46. Majority of them had birth weight 1501‐2500 grams (43.48 %), followed by 1001‐1500 grams (39.13 %) and less than 1000 grams (17.39 %). Majority of neonates had gestational age 35‐37 weeks (53.17 %) as compared to gestational age 28‐34 weeks (47.83 %). Majority neonates received surfactant beyond 6 hrs (82.61 %) as compared to those received surfactant after 6 hrs (17.39 %). Mortality was noted in 12 neonates (26.09 %). Among 46 neonates who received surfactant, 18 neonates received CPAP, out of those 14 neonates (30.43 %) shown improvement with CPAP only. While 28 neonates required ventilatory support, 20 neonates (43.48 %) shown improvement and 8 (17.39 %) died. Surfactant administration have markedly improved the survival of preterm neonates and have resulted in reduced neonatal and infant mortality. Selective or rescue use of surfactant refers to a strategy of providing exogenous surfactant to neonates with established RD.
How to cite this article:
S. Ravikant, Priyanka Akka, Shantala Koujalgi and Supriya Biradar. A Clinical Study of Use of Surfactant in SNCU, Brims, Bidar.
DOI: https://doi.org/10.36478/10.59218/makrjms.2023.12.247.250
URL: https://www.makhillpublications.co/view-article/1815-9346/10.59218/makrjms.2023.12.247.250